Recent Research Analysts’ Ratings Changes for SiBone (SIBN)

A number of research firms have changed their ratings and price targets for SiBone (NASDAQ: SIBN):

• 12/18/2025 – SiBone had its price target raised by analysts at Truist Financial Corporation from $21.00 to $23.00. They now have a “buy” rating on the stock.
• 12/17/2025 – SiBone had its price target raised by analysts at Canaccord Genuity Group Inc. from $26.00 to $27.00. They now have a “buy” rating on the stock.
• 12/17/2025 – SiBone had its price target raised by analysts at Canaccord Genuity Group Inc. from $26.00 to $27.00. They now have a “buy” rating on the stock.
• 12/16/2025 – SiBone had its price target raised by analysts at Needham & Company LLC from $24.00 to $27.00. They now have a “buy” rating on the stock.
• 12/15/2025 – SiBone had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – SiBone had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – SiBone had its price target raised by analysts at Morgan Stanley from $20.00 to $23.00. They now have an “overweight” rating on the stock.
• 11/25/2025 – SiBone had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – SiBone had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity at SiBone

In other news, CEO Laura Francis sold 5,411 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $17.70, for a total value of $95,774.70. Following the transaction, the chief executive officer owned 351,319 shares in the company, valued at $6,218,346.30. This represents a 1.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Anthony J. Recupero sold 3,833 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $17.44, for a total transaction of $66,847.52. Following the completion of the transaction, the insider directly owned 268,144 shares in the company, valued at approximately $4,676,431.36. The trade was a 1.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 185,270 shares of company stock valued at $3,466,814 in the last 90 days. 4.00% of the stock is owned by company insiders.

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.